SMi present their 9th annual conference on...
Asthma & COPD
15th and 16th April 2013, Copthorne Tara Hotel, London, UK

KEY SPEAKERS INCLUDE:

Peter Barnes
Head of Respiratory Medicine
Imperial College School of Medicine

Sebastian Johnston
Professor of Adult Respiratory Medicine
Imperial College

Matthew Catley
Team Leader R&I
AstraZeneca

Emma Hickman
Research Investigator
Novartis

Ewan Walters
Head of Clinical Science
Respiratory/Immunology
TEVA

Donna Finch
Associate Director/Principle Scientist
MedImmune

Liz Hardaker
Investigator II
Novartis

Christopher Stevenson
Research Leader
Roche

Mary Fitzgerald
Executive VP Respiratory
Pulmagen

Geoff Down
Chief Medical Officer
Prosonix

KEY TOPICS FOR 2013:

• Establishing patient phenotyping for efficient and effective therapeutic outcomes
• Overcoming the challenges of clinical trial management and developing novel biomarkers
• Spotlight on inhalation devices and combination therapies
• Comparing and contrasting exacerbations of asthma & COPD alongside treatment options
• Drawing attention to chemokine antagonists and anti-cytokine therapies
• Overcoming steroid resistance in asthma & COPD

PLUS ONE INTERACTIVE HALF-DAY POST CONFERENCE WORKSHOP
Wednesday 17th April 2013, Copthorne Tara, London, UK

Clinical Trial Design in Asthma & COPD
Workshop Leader:
Kevin Bacon, Chief Scientific Officer, Axikin
08.30am – 12.30pm

TO BOOK
www.asthma-copd.co.uk
Register online and receive full information on all of SMi’s conferences
Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
08.30 Registration and Coffee

09.00 Chairman’s Opening Remarks
Peter Barnes, Head of Respiratory Medicine, Imperial College School of Medicine

STEROID RESISTANCE AND ASTHMA MANAGEMENT

09.10 The problem of steroid resistance in asthma and COPD
- Corticosteroid resistance is a major barrier to effective treatment of severe asthma and COPD
- The molecular mechanisms of corticosteroid resistance are now much better defined
- This understanding identifies new therapeutic targets that may lead to reversal of steroid resistance
- Several existing and new drugs are being developed for reversing steroid resistance
Peter Barnes, Head of Respiratory Medicine, Imperial College School of Medicine

09.50 Risk and control in the management of asthma
- What is the difference between risk and control in asthma?
- How do we identify those at risk of an asthma attack?
- Helping people with asthma reduce their risk and improve asthma control
- Implications for asthma management
Samantha Walker, Executive Director, Research & Policy, Asthma UK

10.30 Morning Coffee

PRECLINICAL DEVELOPMENT

11.00 Patient stratification in the development of biologicals
- Asthma patient phenotypes
- Periostin and anti-IL-13
- Mepolizumab
- Mechanistic endotypes
Matthew Catley, Team Leader R&I, AstraZeneca

11.40 Innovative approaches to developing preclinical models for COPD and asthma
- Insights gained from careful characterisations of preclinical models
- Novel bioinformatics methods for comparing preclinical models to clinical samples
- The importance for routinely assessing changes in lung physiology in these preclinical models
Christopher Stevenson, Research Leader, Roche

12.20 Immunotherapy for asthma
- Replication of regulatory processes that occur in non-asthmatic individuals
- Current and future methodologies for immunotherapy
- Immunotherapy with Omalizumab
- Immunotherapy for long-lasting treatment without immunosuppression or immune augmentation
Emma Hickman, Research Investigator, Novartis

13.00 Networking Lunch

CLINICAL TRIAL STUDIES

14.20 New controller therapies for asthma: From small molecules to monoclonal anti-bodies
- New controller therapies for asthma; what is on the horizon?
- CRTh2 antagonists; new controller therapies for asthma
- Different combination approaches for asthma therapy; not just alternative ICS/LABAs
Mary Fitzgerald, Executive VP Respiratory, Pulmagen

15.00 CRTh2 antagonists: basic biology and clinical effects
- Role of CRTh2 in mediating allergic disease
- Pharmacological profile of the CRTh2 antagonist OC000459
- Clinical effects of OC000459 in asthma and allergic rhinoconjunctivitis
Roy Pettipher, Director of Pharmacology, Oxagen

15.40 Afternoon Tea

16.00 Discovery and Development of small molecule CCR3 inhibitors for asthma and allergic rhinitis
- Agonism of CCR3 and its role in allergic inflammation
- Pharmacologic activity of small molecular weight inhibitors in vitro and in vivo
- Clinical development
Kevin Bacon, Chief Scientific Officer, Axikin

16.40 Panel Discussion: Asthma mechanisms AND treatments
Panel Chair: Peter Barnes, Head of Respiratory Medicine, Imperial College School of Medicine
Panellists: All Day One Speakers

17.20 Chairman’s Closing Remarks and Close of Day One

Vitalograph has manufactured respiratory diagnostic equipment for the healthcare industry since 1963 and the name Vitalograph is synonymous with spirometry around the world. The name Vitalograph is also synonymous with quality, as many of our spirometers in everyday use are more than 30 years old! As a consequence, our equipment is favoured by opinion leaders and clinical researchers who need reliable and accurate measurements. We provide a full range of services within respiratory clinical trials and this includes project management, centralized data management, over-reading and a global 24/7 support service. We also have a dedicated integrated solution via our Spirotrac® Centralized Spirometry System that includes site based FeNO measurements, 6MWT, pulse oximetry, challenge testing, 12-lead ECG and our exciting new In2itive™ e-Diary that complies with FDA’s PRO guidance with validated questionnaires. All data is accessible via our VIEWER™ web portal. Also ask about our unique new AIM inhaler trainer for pMDIs and DPIs! www.vitalograph.co.uk

Register online at www.asthma-copd.co.uk • Alternatively fax your registration

Supported by

Sponsored by
08.30  Re-registration and Coffee

09.00  Chairman’s Opening Remarks
Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College School of Medicine

09.10  Comparing exacerbations of Asthma & COPD alongside treatment options
• Aetiology of exacerbations
• Modelling exacerbations in mouse & man
• Mechanisms of exacerbations
• Treatment of exacerbations
Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College School of Medicine

09.50  Developing preclinical models to mimic exacerbations of COPD and asthma
• What are exacerbations of COPD and asthma?
• Current therapies to treat COPD and asthma exacerbations
• In vivo models that mimic aspects of COPD and asthma exacerbations
Liz Hardaker, Investigator II, Novartis

10.30  Morning Coffee

11.00  Case study - A patient with recurrent COPD exacerbations - where is innovation needed to improve care?
• Case presentation of a patient with recurrent exacerbations
• Examples of how new insights into disease and exacerbation phenotypes can improve care
• Horizon scanning for innovations to address treatment gaps
Emma Baker, Professor of Clinical Pharmacology, St George’s, University of London

11.40  Bacterial exacerbation of the altered lung
• Asthma/COPD
• innate immunity
• anti-bacterial immunity
• Epithelium and airway macrophages
Tracey Hussell, Centre Director (MCCIR), Manchester University

12.10  Networking Lunch

13.40  Inhaler therapies to deliver ICS
• Role in delivering active treatments to the lung
• Randomised Clinical Trials [RCTs]
• Modalities to assess PROs
• Overcoming challenges
Ewan Walters, Head of Clinical Science Respiratory/Immunology, TEVA

14.20  Exploring the many credible molecular and cellular mechanisms of COPD pathogenesis
• Exacerbations- balancing pathogen recognition and inflammation
• Emphysema- what drives lung destruction?
• Can both be linked via mechanistic hypotheses?
Donna Finch, Associate Director/Principal Scientist, MedImmune

15.00  Afternoon Tea

15.20  Pharmacodynamic Evaluation of Orally Inhaled Corticosteroids
• Scientific and regulatory background
• Current issues
• Conventional and exploratory methods
• Interpretation and evaluation
Geoff Down, Chief Medical Officer, Prosonix

16.00  Asthma/COPD - phenotypes, biomarkers and implication for stratified therapeutic approaches
• Patient phenotypes
• Application of biomarkers
• Challenges of therapeutic approaches
Harald Renz, Professor of Laboratory Medicine, Philipps-University of Marburg

16.40  Panel Discussion: COPD mechanisms AND treatments
Panel Chair: Sebastian Johnston, Professor of Adult Respiratory Medicine, Imperial College
Panellists: All Day Two Speakers

17.20  Chairman’s Closing Remarks and Close of Day Two

Who should attend this conference:
This event is unmissable for Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in:
• Respiratory Medicine
• Respiratory Pharmacology
• Inflammatory Disease
• Research Immunology
• Pharmacology
• Respiratory Licensing
• Respiratory, Inflammation and Autoimmunity
• Pulmonary Disease
• Immunology
• Respiratory Cell Biology
• Respiratory Therapeutics
• Inhalation Devices
• Medical Devices
• Inflammation Discovery
• Respiratory Medicine Regulation

SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market? Contact Kellee Halliburton, SMI Marketing on +44 (0) 207 827 6194, or email khalliburton@smi-online.co.uk

your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Overview of workshop
This workshop will be a unique interactive session where attendees can explore clinical trial design in asthma and COPD alongside emerging ideas and case studies that can be applied to their own roles and environments. Led by the expertise and experience of Kevin Bacon, of Axikin, the workshop will explore the challenges faced in clinical trial design and facilitate the understanding of unmet needs in clinical trial design for asthma & COPD alongside methods to overcome them.

Why you should attend:
• Discover the benefits of efficient clinical trial design
• Address and overcome the key challenges associated in phase II trials
• Evaluate past experiences and case studies and benefit from lessons learnt
• Network with key industry professionals

Programme
08.30  Registration & Coffee
09.00  Welcome & Introductions
09.10  Anti-inflammatories for Asthma and COPD
• Usual suspects and novel mechanisms
• NCEs vs antibodies
09.45  Positioning Novel Anti-inflammatories
• Clinical vs Pharma perspectives
• Stand-alones vs combination products
10.45  Morning Refreshments
11.00  Pre-clinical Models for Novel Anti-inflammatories
• Current practice and utility
• Translational considerations
12.10  Discussion Session
12.30  Close of Workshop

About the workshop host
As President and Chief Scientific Officer, Dr. Bacon brings almost 20 years of drug discovery, development and management experience to Axikin. Dr. Bacon, founded Axikin’s predecessor, Actimis Pharmaceuticals, in 2004, as a spin-off from Bayer Yakuhin Ltd.’s Respiratory Research Department in Kyoto, Japan, where he served as Vice President of respiratory diseases research. He was latterly involved in negotiating the eventual sale, in a structured acquisition, of Actimis in June 2008, and the formation of Axikin to continue development of additional pre-clinical assets. Prior to joining Bayer AG in 1999, Dr. Bacon was Associate Director of Immunology at Neurocrine Biosciences, Inc., in San Diego, and from 1994 to 1997 a Visiting Scientist at the DNAX Institute for Molecular Biology (a subsidiary of Schering Plough). Dr. Bacon is a co-author on numerous issued and filed patents, actively contributes to journals’ peer review process, and has published over 100 original manuscripts, book chapters and reviews in the field of drug discovery and inflammation biology.

About Axikin
With a rapidly growing portfolio of highly-optimized small molecules, Axikin is well-poised to draw upon significant in-house expertise in anti-inflammatory drug development to move its lead GPCR program towards an IND within an accelerated timeframe. In addition, Axikin has entered into strategic collaborations that will enable target validation, small molecule screening and lead optimization for it’s kinase program.
# SMI Pharmaceutical Forward Planner 2013

## January
- **Biomarkers Summit**
- **Social Media in the Pharma Industry**
  23 – 24 January 2013, London
- **Quality by Design**
  23 – 24 January 2013, London
- **Pre-Filled Syringes**
  28 – 29 January 2013, London
- **Pharmaceutical Microbiology**

## February
- **Parallel Trade**
  6 – 7 February 2013, London
- **Advances and Progress in Drug Design**
  18 – 19 February 2013, London
- **Lyophilisation - Freeze Drying in Pharmaceuticals and Biopharmaceuticals**
  25 – 26 February 2013, London

## March
- **Superbugs & Superdrugs - A Focus on Antibacterials**
  4 – 5 March 2013, London
- **Imaging in Cancer Drug Development**
  13 – 14 March 2013, London
- **Controlled Release**
  18 – 19 March 2013, London
- **Paediatric Clinical Trials**
  20 – 21 March 2013, London

## April
- **Adaptive Designs**
  8 – 9 April 2013, London
- **Asthma & COPD**
  15 – 16 April 2013, London
- **Pharmaceutical Portfolio & Lifecycle Management**
  17 – 18 April 2013, London

## May
- **Generics, Supergenerics & Patent Strategies**
  13 – 14 May 2013, London
- **Pain Therapeutics**
  20 – 21 May 2013, London
- **ADC Summit**
  20 – 21 May 2013, London
- **Clinical Trial Logistics**
  22 – 23 May 2013, London

## June
- **RNAi & Nanotechnology**
  5 – 6 June 2013, London
- **Biobanking**
  24-25 June 2013, London
- **Allergies**
  26 – 27 June 2013, London
- **ADMET**
  26 – 27 June 2013, London

## July
- **Pharmacovigilance**
  1 – 2 July 2013, London
- **Cell Culture**
  3 – 4 July 2013, London
CONFERENCE PRICES

I would like to attend: (Please tick as appropriate)

[ ] Conference & Workshop  Fee: £2098.00 + VAT £2517.60
[ ] Conference only  Fee: £1499.00 + VAT £1798.80
[ ] Workshop only  Fee: £599.00 + VAT £718.80

PROMOTIONAL LITERATURE DISTRIBUTION

[ ] Distribution of your company’s promotional literature to all conference attendees  Fee: £999.00 + VAT £1198.80

GROUP DISCOUNTS AVAILABLE

The conference fee includes refreshments, lunch, conference papers and access to the Document Portal containing all of the presentations.

VENUE

Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SR

Please contact me to book my hotel

Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712

DOCUMENTATION

I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation

[ ] Access to the conference documentation  Price: £499.00 - VAT £598.80
[ ] The Conference Presentations – paper copy  (or only £300 if ordered with the Document Portal)

PAYMENT

Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-064 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

[ ] UK BACS  Sort Code 300009, Account 00936418
[ ] Wire Transfer  Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
[ ] Cheque  We can only accept Sterling cheques drawn on a UK bank.
[ ] Credit Card  [ ] Visa  [ ] MasterCard  [ ] American Express

All credit card payments will be subject to standard credit card charges.

Card No: [ ] 3 digit security on reverse of card, 4 digits for AMEX card

Valid From/Valid To:

CVV Number:

Cardholder’s Name:

Signature: Date:

DELEGATE DETAILS

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Surname:  Forename:  Title:  Company/Organisation:  Email:  Company VAT Number:  Address:

ACCOUNTS DEPT

I agree to be bound by SMi’s Terms and Conditions of Booking.

Signature: Date:

If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not share a place at an event. Please make separate bookings for each delegate.

Cancellations: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the conference documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed within 28 days of the event start date. If you wish to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.

Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here (□) we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

If you have any further queries please call the Events Team on +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk